The Global Hereditary Angioedema Market size was valued at USD 2431.89 Million in 2022 and is projected to reach USD 4881.37 Million by 2030, growing at a CAGR of 9.10% from 2023 to 2030.

Hereditary Angioedema Market Overview:

About 93% of people with hereditary angioedema (HAE) experience recurrent abdominal pain. Many patients who visit emergency rooms, primary care physicians, general surgery departments, and gastroenterology departments are misdiagnosed for years and undergo unnecessary tests, and surgical patients who frequently visit emergency departments, primary care physicians, general surgeons, and gastroenterology departments are misdiagnosed. . You will have to go through unnecessary tests and surgeries. Diagnosing HAE can be difficult because symptoms and seizure location are often inconsistent from episode to episode. Some of the symptoms include unexplained abdominal pain, especially when accompanied by swelling of the face and extremities, suggesting a diagnosis of HAE. Additionally, a family history and radiographic images presenting an edematous bowel also support the diagnosis of HAE.

Hereditary angioedema, or HAE, makes the skin and nose tubes swell up quickly. This is because of a change in the genes called an autosomal dominant trait. HAE can be treated with drugs that are given straight, injected under the skin, or taken by mouth. When a person has this disease, they get stomach cramps and their faces and lungs get bigger. If the tube keeps growing, it could stop, which could be very dangerous. These signs show up when certain proteins are missing or don't work right. These proteins keep fluid going steadily through very small blood veins. (Capillaries). Each person with the illness is affected in a very different way. Skin swelling can hurt, make it hard to do things, and change the way you look, but it's generally not dangerous and doesn't last long. The World Allergy Organization (WAO) has rules about how drugs like esterase inhibitors, kallikrein inhibitors, and other drugs should be used to treat genetic angioedema. Bad changes in the C1NH gene, which is also called the SERPING1 gene or the F12 gene, can lead to HAE. No one knows what always makes it happen.

Hereditary angioedema (HAE) is a rare autosomal dominant disease that causes the face, hands, feet, and pelvic areas to swell up over and over again. HAE can happen to anyone at any age, but most people get it when they are young or going through puberty. There isn't enough of a chemical called C1 esterase inhibitor, which is the trouble. This enzyme helps the body manage how it reacts to inflammation.

Key Market Updates:

• In February 2021, BioCryst Pharmaceuticals Inc. received a positive award from the European Medicines Agency's (EMA) Committee on Medicinal Products for Human Use (CHMP) recommending approval of ORLADEYO (Berotralstat) for the routine prevention of recurrent attacks of hereditary angioedema. It was announced that the opinion was adopted. (HAE) in adult and adolescent patients 12 years of age and older.
• In February 2021, KalVista reported positive results from a phase 2 clinical trial of KVD900 as an on-demand oral treatment for HAE seizures.

Market Key Players:

• Pharming Group NV
• Shire plc
• CSL Limited
• iBio Inc.
• BioCryst Pharmaceuticals
• Others.

key Vendors:
1. The Pharming Group: Pharming Group N.V. is a global biopharmaceutical company that works to improve the lives of people with rare, debilitating, and life-threatening diseases. Pharming is bringing to market and creating an innovative portfolio of protein replacement therapies and precision medicines, such as small molecules, biologics, and gene therapies that are in early to late-stage development. Pharming is based in Leiden, Netherlands, but it has employees all over the world who serve patients in more than 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific. Biotechnology and pharmaceuticals are among their specialties.

2.The company CSL: At CSL, we do what we say we're going to do. We made a promise more than a hundred years ago to save lives and protect the health of people with a wide range of dangerous and long-term illnesses. As the world's top biotechnology company, that promise has never been stronger than it is today. CSL is driven to make and sell a wide range of life-saving medicines to treat conditions like hemophilia and main immune deficiencies, as well as flu vaccines. Our treatments are also used in heart surgery, organ transplants, and the care of people who have been burned.

As a world leader, CSL works with the medical and patient groups to improve access to therapies, advance scientific knowledge, support the next generation of medical researchers, and get our employees involved in helping their local communities. Our world-class commercial operation, large and focused R&D team, and operational excellence allow us to find innovations that patients and providers want, create them successfully, and deliver them reliably.CSL has made a name for itself as an organization that cares about people and follows through on what it promises. Our future has never looked better than it does right now. Complex biological, vaccines, plasma and plasma-derived medicines, and biotechnology are some of the things they are good at.

3.iBio Inc.: At iBio, we are using our RubrYc® Discovery Platform to work on complicated and difficult drug targets. Our goal is to make safer and more effective immunotherapies for cancers that are hard to treat. We want to live in a world where finding new drugs isn't left up to chance, but instead is led by AI to make therapeutic development smarter, more accurate, and, in the end, faster.

We are going after hard-to-drug targets with more promise and less competition with our RubrYc Discovery Platform. In our pipeline, we have nine immuno-oncology options, some of which could be used to treat solid tumors, glioblastoma, and head and neck cancers. One of the biggest problems with making antibody drugs is that standard drug discovery methods use a lot of randomness. To make an antibody with a certain set of traits, scientists have to try many times until they get the best result, which often happens by chance. Monoclonal antibodies, Biopharmaceuticals, drug discovery, artificial intelligence, drug research, and immuno-oncology are some of the things this company specializes in.

4.BioCryst Pharmaceuticals, Inc.: BioCryst is a biotech company in the commercial stage whose goal is to give patients extraordinary drugs that help them live normal lives. We are very interested in making new medicines for people with rare and dangerous diseases.

Our European headquarters are in Dublin, Ireland, and our US offices are in Durham, North Carolina. Our Discovery Center of Excellence is in Birmingham, Alabama. With our knowledge of drug discovery, clinical development, and regulatory affairs, we are moving clinical projects forward and making new compounds with our own discovery engine. Drug Discovery, Clinical Development, Rare Diseases, Regulatory Affairs, and Product Commercialization are the company's main areas of expertise.

Major Market Segments Covered in Hereditary Angioedema Market Industry Research:
By Type:

• C1 Esterase Inhibitor
• Kallikrein Inhibitor
• Selective Bradykinin B2 Receptor Antagonist

By Application:

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

By Region:
North America is expected to dominate the overall hereditary angioedema market over the forecast period, owing to the presence of key players, increasing awareness programs and research organizations regarding treatment of the condition, and establishment of healthcare infrastructure. Rising government initiatives, growing research partnerships and strong pipelines are the major growth drivers for the market.

For example, Ionis Pharmaceuticals, a California-based biotech company, has an antisense drug, IONIS-PKK-LRx, in its pipeline for ligand binding (LICA) investigations. The company is evaluating a drug molecule to reduce the production of prekallikrein (PKK) to treat patients with hereditary angioedema. In September 2021, Cycle Pharmaceuticals launched SAJAZIR (Icatibant) Injection, a new treatment option for patients with hereditary angioedema (HAE) that has been approved by the US FDA. There are many government and non-government funded research institutes in the region. For example, the National Center for Advancing Translational Sciences (NCATS) is entirely focused on esoteric tests for the treatment and cure of rare diseases. NCATS aims to obtain collaborative projects to study common themes and causes of related diseases in order to accelerate the development of treatments. Hence, these factors are expected to give the market a lucrative growth in the coming years.

• North America
• US
• Canada
• Mexico
• Rest of North America
• Europe
  • Denmark
  • Finland
  • Iceland
  • Sweden
  • Norway
  • Belgium
  • The Netherlands
  • Luxembourg
• Germany
• France
• Italy
• Spain
• UK
• Nordic Countries
• Benelux Union
• Rest of Europe
• Asia-Pacific
  • Indonesia
  • Thailand
  • Malaysia
  • Singapore
  • Rest of Southeast Asia
• Japan
• China
• India
• Australia
• South Korea
• Southeast Asia
• Rest of Asia-Pacific
• The Middle East & Africa
• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest of the Middle East & Africa
• Latin America
• Brazil
• Argentina
• Rest of Latin America

Significant Market Dynamics:

Dynamics:

• Growing awareness and diagnosis of HAE
• Increasing availability of effective treatment options
• Growing demand for prophylactic therapies
• Emergence of new therapies such as gene therapy and RNA interference (RNAi)

Restraints:

• Limited patient pool due to the rarity of the disease
• High cost of treatment and limited insurance coverage
• Limited availability of specialized healthcare facilities
• Increasing competition from generic drugs and biosimilars

Trends:

• Growing focus on personalized medicine and precision therapies
• Increasing adoption of prophylactic treatment options
• Growing popularity of self-administered therapies
• Emergence of new delivery systems such as subcutaneous injections

Drivers:

• Rising prevalence of HAE
• Increasing demand for effective and safe treatment options
• Growing investments in research and development
• Favorable regulatory environment for rare disease treatments

Challenges:

• Limited awareness and understanding of the disease among healthcare professionals and the general population
• High cost of developing and bringing new therapies to market
• Complexity of diagnosis and treatment management
• Limited research funding and resources

Opportunities:

• Growing demand for novel therapies with improved safety and efficacy profiles
• Increasing collaboration among pharmaceutical companies, academic institutions, and patient organizations
• Growing availability of patient support services and resources
• Expanding global market potential with the emergence of new markets in developing countries

 Scope of report :

Report Attribute	Details
Study Period	2017-2030
Base Year	2022
Estimated year	2023
Forecast period	2023-2030
Historic Period	2017-2022
Units	Value (USD Billion)
Growth Rate	CAGR of 9.1% from 2023 to 2030
By Type	C1 Esterase Inhibitor Kallikrein Inhibitor Selective Bradykinin B2 Receptor Antagonist
By Application	Retail Pharmacies Hospital Pharmacies Online Pharmacies
By Companies	Pharming Group NV Shire plc CSL Limited iBio Inc. BioCryst Pharmaceuticals Others.
Regional Scope	North America Europe Asia-Pacific The Middle East & Africa Latin America
Reasons to Purchase this Report and Customization Scope	6-month post-sale analyst assistance. 10% Free Customization and 15 Company Profiles in addition to the ones specified

Conclusion: 

In conclusion, research in the last few decades has made a huge step forward in figuring out how AEs happen and in making safe and successful new medicines to treat acute AE symptoms or control disease activity through preventive therapy. In the future, more work needs to be done to raise disease knowledge, make diagnostic tools easier to understand, and maybe even find biomarkers that can predict how a disease will progress. Smart algorithms, harmonized databases, and data sharing made possible by technology will help specialists and individuals/caregivers work together better to help patients get better care and understand what they really need. Advances in pharmacological treatment aim to give people a normal life by making prevention methods better and making sure all drugs are safe, effective, and easy to take a Future goals should be to make it easier for people all over the world to get diagnostic tools, successful medicines, and maybe even genetic cures for different types of HAE.